Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 27517095)

Published in JCI Insight on July 21, 2016

Authors

Kong Chen1, Brian T Campfield2, Sally E Wenzel3, Jeremy P McAleer1, James L Kreindler4, Geoffrey Kurland5, Radha Gopal1, Ting Wang6, Wei Chen6, Taylor Eddens1, Kathleen M Quinn1, Mike M Myerburg7, William T Horne1, Jose M Lora8, Brian K Albrecht8, Joseph M Pilewski7, Jay K Kolls1

Author Affiliations

1: Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA.
2: Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, USA; University of Pittsburgh, Division of Pediatric Infectious Diseases, Department of Pediatrics, Pittsburgh, Pennsylvania, USA.
3: University of Pittsburgh Asthma Institute at UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
4: Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
5: Division of Pediatric Pulmonology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
6: Division of Pulmonary Medicine, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
7: Division of Pulmonary, Allergy, and Critical Care Medicine, UPMC, Pittsburgh, Pennsylvania, USA.
8: Constellation Pharmaceuticals Inc., Cambridge, Massachusetts, USA.

Articles cited by this

Lebrikizumab treatment in adults with asthma. N Engl J Med (2011) 8.07

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51

IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol (2007) 4.54

Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology (2010) 3.51

Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol (2005) 3.47

Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature (2012) 2.94

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med (2014) 2.63

The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev (2008) 2.36

TH17 cells in asthma and COPD. Annu Rev Physiol (2010) 2.36

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 2.24

The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24

Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med (2004) 2.19

A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A (2002) 2.17

BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A (2012) 1.93

IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS One (2011) 1.61

Autism-like syndrome is induced by pharmacological suppression of BET proteins in young mice. J Exp Med (2015) 1.58

Mortality factor 4 like 1 protein mediates epithelial cell death in a mouse model of pneumonia. Sci Transl Med (2015) 1.44

Inflammatory monocytes orchestrate innate antifungal immunity in the lung. PLoS Pathog (2014) 1.39

BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med (2013) 1.33

The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa. J Infect Dis (2007) 1.26

Acute regulation of the epithelial sodium channel in airway epithelia by proteases and trafficking. Am J Respir Cell Mol Biol (2010) 1.18

Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir Res (2009) 1.16

Interleukin-23-mediated inflammation in Pseudomonas aeruginosa pulmonary infection. Infect Immun (2011) 1.04

Interleukin-17A induces bicarbonate secretion in normal human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol (2008) 1.01

Membrane-bound eotaxin-3 mediates eosinophil transepithelial migration in IL-4-stimulated epithelial cells. Eur J Immunol (2006) 1.00

Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes. J Allergy Clin Immunol (2012) 1.00

T cell-mediated host immune defenses in the lung. Annu Rev Immunol (2013) 1.00

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia (2014) 0.98

BET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle. J Biol Chem (2015) 0.93

Intelectin-1 is a prominent protein constituent of pathologic mucus associated with eosinophilic airway inflammation in asthma. Am J Respir Crit Care Med (2014) 0.91

CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET. Am J Physiol Lung Cell Mol Physiol (2015) 0.87

Innate Lymphoid Cells Are the Predominant Source of IL-17A during the Early Pathogenesis of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med (2016) 0.85

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis (2014) 0.84

Antibiotic and anti-inflammatory therapies for cystic fibrosis. Cold Spring Harb Perspect Med (2013) 0.84

RNA-seq in Pulmonary Medicine: How Much Is Enough? Am J Respir Crit Care Med (2015) 0.81